SAWAI GROUP HOLDINGS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,687 JPY | -4.37% |
|
-6.95% | +9.18% |
| Sales 2024 | 177B 1.13B | Sales 2025 * | 202B 1.29B | Capitalization | 249B 1.59B |
|---|---|---|---|---|---|
| Net income 2024 | 13.7B 87.31M | Net income 2025 * | 29.05B 185M | EV / Sales 2024 | 1.81 x |
| Net Debt 2024 | 56.36B 359M | Net Debt 2025 * | 44.3B 282M | EV / Sales 2025 * | 1.45 x |
| P/E ratio 2024 |
19.3
x | P/E ratio 2025 * |
9.14
x | Employees | 3,393 |
| Yield 2024 |
2.16% | Yield 2025 * |
2.61% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sawai Group Holdings Co., Ltd.
| 1 day | -4.37% | ||
| 1 week | -6.95% | ||
| Current month | -6.95% | ||
| 1 month | -0.19% | ||
| 3 months | -8.44% | ||
| 6 months | +14.70% | ||
| Current year | +9.18% |
1 week
5 668.00
6 287.00
1 month
5 614.006 645.00
Current year
5 104.006 645.00
1 year
3 305.006 645.00
3 years
3 255.006 645.00
5 years
3 255.007 430.00
10 years
3 255.008 560.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 21-03-31 |
| President | 66 | 21-03-31 | |
Toru Terashima
BRD | Director/Board Member | 64 | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 21-03-31 |
Kenzo Sawai
BRD | Director/Board Member | 56 | 21-03-31 |
Masatoshi Ohara
BRD | Director/Board Member | 73 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 14 M€ | +12.67% | ||
| 0.04% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 5,687 | -4.37% | 625,900 |
| 24-06-06 | 5,947 | -0.18% | 277,100 |
| 24-06-05 | 5,958 | -1.67% | 316,600 |
| 24-06-04 | 6,059 | -0.88% | 266,800 |
| 24-06-03 | 6,113 | +0.02% | 176,400 |
Delayed Quote Japan Exchange, June 07, 2024 at 02:00 am EDT
More quotes
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5,687
JPY
Average target price
6,840
JPY
Spread / Average Target
+20.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.18% | 1.59B | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 4887 Stock
